SCHEMBL16806458

SCHEMBL16806458

CC(c1oc(=O)c2ccccc2c1-c1ccc(CN2CCN(CCO)CC2)s1)n1nc(-c2cc(O)cc(F)c2)c2c(N)ncnc21

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 18/20 0.51
▸ PIK3CB P42338 15/20 0.51
▸ PIK3CA P42336 12/20 0.51
▸ PIK3CG P48736 12/20 0.51
▸ ABL1 P00519 1/20 0.46
▸ EGFR P00533 1/20 0.46
▸ HCK P08631 1/20 0.46
▸ SRC P12931 1/20 0.46
▸ KDR P35968 1/20 0.46
▸ MTOR P42345 1/20 0.46
▸ EPHB4 P54760 1/20 0.46
▸ PRKDC P78527 1/20 0.46
▸ PI4KB Q9UBF8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16783436 1.00 PIK3CD (0.51) PIK3CDPIK3CBPIK3CAPIK3CGABL1
Hydrochloric Acid SCHEMBL16783882 0.99 PIK3CD (0.50) PIK3CDPIK3CBPIK3CAPIK3CGABL1
SCHEMBL16783415 0.95 PIK3CD (0.52) PIK3CDPIK3CBPIK3CAPIK3CGABL1
Hydrochloric Acid SCHEMBL21327917 0.94 PIK3CD (0.51) PIK3CDPIK3CBPIK3CAPIK3CGABL1
SCHEMBL16783531 0.94 PIK3CD (0.53) PIK3CDPIK3CBPIK3CAPIK3CGABL1
SCHEMBL16783570 0.93 PIK3CD (0.52) PIK3CDPIK3CBPIK3CAPIK3CGABL1
Hydrochloric Acid SCHEMBL16783569 0.93 PIK3CD (0.52) PIK3CDPIK3CBPIK3CAPIK3CGABL1
Hydrochloric Acid SCHEMBL16783821 0.93 PIK3CD (0.52) PIK3CDPIK3CBPIK3CAPIK3CGABL1
SCHEMBL16783641 0.93 PIK3CD (0.56) PIK3CDPIK3CBPIK3CAPIK3CGABL1
Hydrochloric Acid SCHEMBL16783865 0.92 PIK3CD (0.55) PIK3CDPIK3CBPIK3CAPIK3CGABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3083617-B1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARM SPA (IT) 2019-09-11 — — EP claimed
EP-3083617-B1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARM SPA (IT) 2019-09-11 — — EP disclosed
EP-3083617-A1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2016-10-26 — — EP disclosed
US-9321776-B2 Isochromene derivatives as phoshoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-04-26 — — US disclosed
US-9321776-B2 Isochromene derivatives as phoshoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2016-04-26 — — US disclosed
WO-2015091685-A1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-06-25 — — WO disclosed
WO-2015091685-A1 ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-06-25 — — WO disclosed
US-20150166549-A1 ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-06-18 — — US disclosed
US-20150166549-A1 ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2015-06-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166549-A1 ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS PIKFYVE, IP6K2, IP6K3 PIK3CD 15/4885PIK3CB 12/4885PIK3CA 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback